3PO manufacturers
- 3PO
-
- $52.00
-
2026-07-14
- CAS:18550-98-6
- Purity: 99.56%
- Supply Ability: 10g
|
| Product Name: | 3PO | | Synonyms: | 3PO (inhibitor of glucose metabolism);(E)-3-Pyridin-3-yl-1-pyridin-4-yl-propenone;3 PO;3-PO;2-Propen-1-one, 3-(3-pyridinyl)-1-(4-pyridinyl)-, (2E)-;3PO >=98% (HPLC);inhibitor of glucose metabolism;3PO, 10 mM in DMSO;3PO[SML1343] | | CAS: | 18550-98-6 | | MF: | C13H10N2O | | MW: | 210.23 | | EINECS: | | | Product Categories: | | | Mol File: | 18550-98-6.mol |  |
| Boiling point | 387.8±42.0 °C(Predicted) | | density | 1.192±0.06 g/cm3(Predicted) | | storage temp. | 2-8°C | | solubility | Soluble in DMSO (up to 15 mg/ml) or in Ethanol (up to 5 mg/ml) | | form | powder | | pka | 3.49±0.11(Predicted) | | color | white to beige | | Stability: | Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months. | | InChI | InChI=1S/C13H10N2O/c16-13(12-5-8-14-9-6-12)4-3-11-2-1-7-15-10-11/h1-10H/b4-3+ | | InChIKey | UOWGYMNWMDNSTL-ONEGZZNKSA-N | | SMILES | C(C1C=CN=CC=1)(=O)/C=C/C1=CC=CN=C1 |
| WGK Germany | WGK 3 | | Storage Class | 11 - Combustible Solids |
| Description | 3PO (18550-98-6) is an inhibitor of the metabolic enzyme 6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3). PFKFB3 is constitutively expressed by neoplastic cells and is required for the high glycolytic rate (Warburg Effect) of these cells. 3PO inhibits PFKFB3 (IC50= 1.4 – 24 μM for various cancer cell lines), suppresses glucose uptake, and lowers intracellular concentrations of Fru-2,6-BP, lactate, ATP, NAD+, and NADH.1 Inhibition of cancer cell metabolism via blocking the action of PFKFB3 has been studied in various models.2-4 Inhibition of PFKFB3 has been shown to induce autophagy as a survival mechanism in cancer cells.5 3PO has also been used to reduce pathological angiogenesis.6 | | Uses | 3PO is an inhibitor of PFKFB3. 3PO attenuates the proliferation of several cancer cell lines with IC50s of 1.4-24 μmol/L. 3PO suppresses glucose uptake and decreases the intracellular concentration of Fru-2,6-BP, lactate, ATP, NAD+ and NADH. 3PO can be used for the research of cancer[1]. | | Definition | ChEBI: 3PO is a member of the class of pyridines that is pyridine substituted by a 3-oxo-3-(pyridin-4-yl)prop-1-en-1-yl group at position 3. An inhibitor of PFKFB3 kinase, an enzyme with a key role in glycolysis. It has a role as an antineoplastic agent, an angiogenesis inhibitor, an autophagy inducer, an apoptosis inducer and an EC 2.7.1.105 (6-phosphofructo-2-kinase) inhibitor. It is a member of pyridines and an enone. | | Biochem/physiol Actions | 3PO is a potent and selective inhibitor of PFKFB3 (6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase) that reduces glycolytic flux and suppresses glucose uptake. 3PO is selectively cytostatic to transformed cells and suppresses the growth of established tumor in mice. | | in vivo | 3PO (0.07 mg/g; i.p. once per day for 14 days) inhibits the growth of Lewis lung carcinoma xenografts in C57Bl/6 mice[1].
3PO (0.07 mg/g; i.p. three sequential daily injections followed by 3 off days for 14 days) inhibits the tumor growth in BALB/c athymic mice[1].
3PO (0.07 mg/g; i.p. two daily injections followed a 7-day rest for 14 days) inhibits the tumor growth in BALB/c athymic mice[1].
3PO (0.07 mg/g; i.p. once) inhibits Fru-2,6-BP and glucose uptake in C57Bl/6 mice[1]. | Animal Model: | Female C57Bl/6 mice with Lewis lung carcinoma xenografts[1] | | Dosage: | 0.07 mg/g | | Administration: | Intraperitoneal injection; 0.07 mg/g once a day; for 14 days | | Result: | Suppressed the growth of Lewis lung carcinoma xenografts in C57Bl/6 mice compared to the control group. |
| Animal Model: | Female BALB/c athymic mice with MDA-MB231 human breast adenocarcinoma xenografts[1] | | Dosage: | 0.07 mg/g | | Administration: | Intraperitoneal injection; 0.07 mg/g three sequential daily injections of either DMSO or 3PO followed by 3 off days; for 14 days | | Result: | Suppressed xenograft tumorigenic growth of MDA-MB231 cells compared with the controls. |
| Animal Model: | Female BALB/c athymic mice with HL-60 leukemia xenografts[1] | | Dosage: | 0.07 mg/g | | Administration: | Intraperitoneal injection; 0.07 mg/g two daily injections followed a 7-day rest; for 14 days | | Result: | Suppressed xenograft tumorigenic growth of HL-60 leukemia compared with the controls, especially from the second administration cycle. |
| Animal Model: | Female C57Bl/6 mice with Lewis lung carcinoma xenografts[1] | | Dosage: | 0.07 mg/g | | Administration: | Intraperitoneal injection; once | | Result: | Decreased Fru-2,6-BP and glucose uptake in C57Bl/6 mice compared to control group. |
| | References | [1] BRIAN CLEM. Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth.[J]. Molecular Cancer Therapeutics, 2008: 110-120. DOI:10.1158/1535-7163.mct-07-0482
[2] BRIAN F CLEM. Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancer.[J]. Molecular Cancer Therapeutics, 2013, 12 8: 1461-1470. DOI:10.1158/1535-7163.mct-13-0097
[3] MICHAEL A LEA Charles desBordes Mansour Altayyar. Inhibition of Growth of Bladder Cancer Cells by 3-(3-Pyridinyl)-1-(4-pyridinyl)-2-propen-1-one in Combination with Other Compounds Affecting Glucose Metabolism.[J]. Anticancer research, 2015: 5889-5899.
[4] MICHAEL A LEA Charles D Yolanda Guzman. Inhibition of Growth by Combined Treatment with Inhibitors of Lactate Dehydrogenase and either Phenformin or Inhibitors of 6-Phosphofructo-2-kinase/Fructose-2,6-bisphosphatase 3.[J]. Anticancer research, 2016, 36 4: 1479-1488.
[5] ALDEN C KLARER. Inhibition of 6-phosphofructo-2-kinase (PFKFB3) induces autophagy as a survival mechanism.[J]. Cancer & Metabolism, 2014, 2 1: 2. DOI:10.1186/2049-3002-2-2
[6] SANDRA SCHOORS. Partial and transient reduction of glycolysis by PFKFB3 blockade reduces pathological angiogenesis.[J]. Cell metabolism, 2014, 19 1: 37-48. DOI:10.1016/j.cmet.2013.11.008 |
| | 3PO Preparation Products And Raw materials |
|